Jennifer Huber - AN2 Therapeutics Senior Quality
| ANTX Stock | USD 1.39 0.05 3.73% |
Executive
Jennifer Huber is Senior Quality of AN2 Therapeutics
| Address | 1800 El Camino Real, Menlo Park, CA, United States, 94027 |
| Phone | 650 331 9090 |
| Web | https://www.an2therapeutics.com |
AN2 Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4289) % which means that it has lost $0.4289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6948) %, meaning that it created substantial loss on money invested by shareholders. AN2 Therapeutics' management efficiency ratios could be used to measure how well AN2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.59 in 2024. At this time, AN2 Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.6 M in 2024, whereas Total Assets are likely to drop slightly above 69.6 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Stefan Abele | Pharvaris BV | 54 | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Ling Zhou | Adagene | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Mary JD | PepGen | 56 | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Bruce Close | Acrivon Therapeutics, Common | N/A | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Emiko Bryant | PepGen | N/A | |
| Robert Ticktin | Pmv Pharmaceuticals | 62 | |
| Yan MBA | Adagene | 49 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Michael Deperro | Rezolute | N/A | |
Management Performance
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.43 |
AN2 Therapeutics Leadership Team
Elected by the shareholders, the AN2 Therapeutics' board of directors comprises two types of representatives: AN2 Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AN2. The board's role is to monitor AN2 Therapeutics' management team and ensure that shareholders' interests are well served. AN2 Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AN2 Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Chief Officer | ||
| Eric Easom, CEO, Cofounder | ||
| Paul MD, Chief Officer | ||
| Sanjay Chanda, Chief Officer | ||
| Josh Eizen, Chief Sec | ||
| Jennifer Huber, Senior Quality | ||
| Michael Alley, CoFounder Biology | ||
| Joshua JD, Chief Secretary | ||
| Lucy CPA, Principal CFO | ||
| MD FACP, CoFounder Advisor | ||
| Joseph Zakrzewski, Cofounder Chairman |
AN2 Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is AN2 Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (55.21 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Shares Owned By Insiders | 21.63 % | ||||
| Shares Owned By Institutions | 52.31 % | ||||
| Number Of Shares Shorted | 133.57 K | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.46 X | ||||
| EBITDA | 4.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.